Dataset from A Phase I, First-in-Human, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors With Anthracycline-Induced Cardiomyopathy

The primary purpose of this study is to examine the safety and feasibility of delivering
allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer
survivors with left ventricular (LV) dysfunction secondary to anthracycline-induced
cardiomyopathy (AIC).

The secondary purpose of this study is to obtain preliminary evidence for therapeutic
efficacy of allo-MSCs delivered by transendocardial injection to cancer survivors with LV
dysfunction secondary to AIC.